Stay updated on Pembrolizumab in Advanced Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced Urothelial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced Urothelial Cancer Clinical Trial page
- Check6 days agoChange DetectedA notice was added announcing NIH’s transition terminology, with links to updates and FAQs.SummaryDifference1%

- Check13 days agoChange DetectedThe site footer revision changed from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoChange DetectedThe footer’s site revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study details with an access-denied screen. This means users cannot view the trial information or related content on that page.SummaryDifference20%

- Check63 days agoChange DetectedAn NIH grant/contract identifier (2014) was added to the study identifiers, and the page now reflects Revision: v3.6.6, replacing the prior v3.6.5.SummaryDifference0.1%

- Check83 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing Revision: v3.6.4, representing a small update to the posted page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Advanced Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced Urothelial Cancer Clinical Trial page.